Ana Maria Henao Restrepo | Implementation Research and Economic Analysis, Initiative for Vaccine Research
World Health Organization

Ana Maria Henao Restrepo, Implementation Research and Economic Analysis, Initiative for Vaccine Research, World Health Organization

ince 2002, Dr Henao-Restrepo has been a medical officer at the Initiative for Vaccine Research (IVR), Department of Immunization Vaccines and Biologicals at the World Health Organization (WHO). Dr Henao-Restrepo is currently the Team Leader for implementation research at IVR. Among other issues, Dr. Henao-Restrepo is responsible for a project to review the evidence and inform the development of adjusted policy recommendations for vaccines currently in use in the immunization programme. She also led a project to develop and assess a measles aerosol vaccine. Dr Henao Restrepo has also contributed to the Expanded Programme of Immunization and served as the WHO global focal point for the measles and rubella control efforts between 1999 and 2002. Prior to arriving in WHO Geneva in 1997, Dr. Henao- Restrepo completed a peripatic 10-year career in international health with WHO with assignments in the WHO South East Asia Regional Office, Eastern Africa, Nicaragua, El Salvador, and Colombia where she worked in the implementation and evaluation of strategies to eradicate poliomyelitis and, eliminate measles and maternal and neonatal tetanus. In August 2014, Dr Henao-Restrepo was temporarily assigned to the Ebola Research and Development team. She coordinated the WHO work on Phase 3 vaccine trials and led the Ring vaccination trial in Guinea and Sierra Leone.


DC Pre-congress WS day April 2 @ 2:00

Workshop D:The role of vaccines in preventing outbreaks, through natural causes or biothreats: The WHO blueprint

It only takes natural outbreaks like the Ebola and Zika viruses to highlight the danger and fragile balance we live in. To ensure global and international security, important decisions need to be made in stockpiling and prioritizing research efforts, however there is a lack of vaccine manufacturers producing these countermeasure treatments. Participate in this workshop to understand the rationale for developers to produce these lower commercial interest vaccines, and the challenges/opportunities associated in working with the government.

Public-private partnerships for pandemic influenza and emerging infectious disease vaccine preparedness and response

The WHO blueprint: Nipah, MERS, LASSA, Zika, Chik

Modelling for dangerous pathogens and estimating vaccine efficacy

back to speakers